Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 8/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25316534 | 0.80 | NUDT1 (0.32) | NUDT1CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL26622776 | 0.80 | APLNR (0.39) | NUDT1CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL25922708 | 0.78 | NUDT1 (0.31) | NUDT1CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL18149303 | 0.78 | KDM4E (0.32) | NUDT1CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL25922712 | 0.75 | NUDT1 (0.33) | NUDT1CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL21375246 | 0.75 | KDM4E (0.32) | KDM4ERAB9A | |
| SCHEMBL599774 | 0.74 | KDM4E (0.37) | KDM4ENPC1RAB9A | |
| SCHEMBL15651900 | 0.74 | KDM4E (0.37) | NUDT1KDM4ERAB9A | |
| SCHEMBL16905563 | 0.70 | KDM4E (0.32) | KDM4ERAB9A | |
| SCHEMBL14595543 | 0.68 | MAP4K4 (0.36) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | BRAF, RAF1, NRAS | NUDT1 3491/4885CCNA2 455/4885CDK2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.